1. Home
  2. Expertise
  3. Global Manufacturing Facilities

Delivering quality at scale

Delivering quality at scale

We have over 36 strategically located, manufacturing facilities catering to diverse market requirements on demand – including India, USA, China, Russia, Egypt, Mexico, Indonesia and Saudi Arabia.

Key Highlights

Asia’s Largest API SEZ manufacturing complex for APIs – with 1,000+ reactors and spread over 500 acres

Largest Finished Dosage SEZ facility

Largest manufacturing facilities ready to deliver on any scale in quick time
Stringent operating procedures and compliance to current Good Manufacturing Practices (cGMP) and applicable regulatory requirements
Continuous investments in upgradation of manufacturing facilities with emphasis on deploying advanced machinery and adopting latest technologies
A closer look at our state-of-the-art facilities

Ascent Pharmaceuticals Inc

Central Islip, New York – USA

Amarox Pharma

Mexico

Renhe-Hetero

China

Makiz Pharma LLC

Russia

Pharmed Healthcare

Egypt

Hetero Chemical Complex for APIs

Nakkapally – Visakhapatnam, India

Largest Formulations facility

Jadcherla – Hyderabad, India

API facility

Bonthapally – Hyderabad, India

API facility

Kazipally – Hyderabad, India

Formulations facility

Sangareddy District - Hyderabad, India

Formulations facility

Jeedimetla - Hyderabad, India

Biosimilars facility

Jadcherla – Hyderabad, India

Formulations facility

Baddi – Himachal Pradesh, India

Oncology facility

Jadcherla – Hyderabad, India

Injectable facility

Karkapatla - Hyderabad, India

Capacities

Large capacities to meet global demand

Active Pharmaceutical Ingredients (APIs)

Reactor volume (per annum)

7,320 KL

Installed capacity (per annum)

36,878 MT

Finished Dosages

Tablets (per annum)

54 billion

Pellets (per annum)

360 tonnes

Injectables* (per annum)

180 million

Capsules (per annum)

7 billion

Liquids (per annum)

23 million

*Includes lyophilized, liquids and powder

Biosimilars

Bioreactor capacities

10 KL

Batches produced (per annum)

135

Formulation manufacturing PFS
(units per annum)

750 million

Vials (units per annum)

600 million

Vaccine production capacity
(units per annum)

120 million

Explore more

Know more about our Quality Focus

Read More